|
MedImmune
MedImmune, LLC was a wholly owned subsidiary of AstraZeneca before February 14, 2019, when it was announced that the MedImmune name and branding would be discontinued in favor of AstraZeneca. MedImmune was founded in 1988 as Molecular Vaccines, Inc, and was purchased in 2007 for $15.6 billion. Its main offices were located in Gaithersburg, MD, Cambridge, UK, and Mountain View, CA. It produced ''Palivizumab, Synagis'', a drug for the prevention of respiratory infections in infants, which accounted for United States dollar, US$ 1.06 billion of its United States dollar, US$ 1.2 billion in revenue for 2005, and ''FluMist'', a nasal spray influenza vaccine introduced in 2004. MedImmune acquired ''FluMist'' when it purchased Aviron in 2002 for United States dollar, US$ 1.5 billion. ''FluMist'' sales totaled United States dollar, US$ 104 million in 2008, United States dollar, US$ 54.8 million in 2007, and United States dollar, US$ 36.4 million in 2006. ''FluMist'' was approved for chil ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Cambridge Antibody Technology
Cambridge Antibody Technology Group Plc, (commonly referred to as CAT) was a biotechnology company headquartered in Cambridge, England. Its core focus was on antibody therapeutics, primarily using phage display, Phage Display and ribosome display, Ribosome Display technology. Phage display, Phage Display Technology was used by CAT to create adalimumab, the first fully human antibody blockbuster drug. Humira, the brand name of adalimumab, is an anti-TNF antibody discovered by CAT as D2E7, then developed in the clinic and marketed by Abbvie, formerly Abbott Laboratories. CAT was also behind belimumab, the anti-BlyS antibody drug marketed as Benlysta and the first new approved drug for systemic lupus in more than 50 years. In 2018, the Nobel Prize organisation awarded one quarter of the Nobel Prize in Chemistry to a founding member of CAT, Greg Winter, Sir Greg Winter FRS "for the phage display of peptides and antibodies". Founded in 1989, CAT was acquired by AstraZeneca for £702 ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
AstraZeneca
AstraZeneca plc () (AZ) is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, UK. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. The company was founded in 1999 through the merger of the Swedish Astra AB and the British Zeneca Group (itself formed by the demerger of the pharmaceutical operations of Imperial Chemical Industries in 1993). Its portfolio includes primary and speciality care, coverage for rare diseases, and a robust global presence across various regions. Since the merger it has been among the world's largest pharmaceutical companies and has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014). It has its research and development conc ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
FluMist
Live attenuated influenza vaccine (LAIV) is a type of influenza vaccine in the form of a nasal spray that is recommended for the prevention of influenza. It is an attenuated live vaccine, unlike other influenza vaccines, which are inactivated vaccines. Live attenuated influenza vaccine is administered intranasally, while inactivated vaccines are administered by intramuscular injection. Live attenuated influenza vaccine is sold under the brand names FluMist and FluMist Quadrivalent in the United States; and the brand name Fluenz Tetra in the European Union. FluMist was first introduced in 2003 by MedImmune. In the United States, FluMist is approved for self- or caregiver-administration. It is the first influenza vaccine that does not need to be administered by a health care provider. Medical uses The live attenuated influenza vaccine is used to provide protection against the flu caused by infection with influenza viruses. Contraindications The use of the live attenuated infl ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Moxetumomab Pasudotox
Moxetumomab pasudotox, sold under the brand name Lumoxiti, is an anti-CD22 immunotoxin medication for the treatment of adults with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog. Moxetumomab pasudotox is a CD22-directed cytotoxin and is the first of this type of treatment for adults with HCL. The drug consists of the binding fragment (Fv) of an anti-CD22 antibody fused to a toxin called PE38. This toxin is a 38 kDa fragment of Pseudomonas exotoxin A. Hairy cell leukemia (HCL) is a rare, slow-growing cancer of the blood in which the bone marrow makes too many B cells (lymphocytes), a type of white blood cell that fights infection. HCL is named after these extra B cells which look “hairy” when viewed under a microscope. As the number of leukemia cells increases, fewer healthy white blood cells, red blood cells and platelets are produced. Medical uses Moxetumomab ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Tralokinumab
Tralokinumab sold under the brand names Adtralza (EU/UK) and Adbry (US) among others, is a human monoclonal antibody used for the treatment of atopic dermatitis. Tralokinumab targets the cytokine interleukin 13. The most common side effects include upper respiratory tract infections (colds and other infections of the nose and throat), reactions at the injection site, and redness and discomfort in the eye. Tralokinumab was approved for medical use in the European Union and in the United Kingdom in June 2021. It was approved for medical use in the United States in December 2021. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication. Medical uses Tralokinumab is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy. In the United States, tralokinumab is indicated for the treatment of moderate-to-severe atopic dermatitis in adults whose disease is not adequately controlled wit ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
H5N1 Clinical Trials
H5N1 clinical trials are clinical trials concerning H5N1 vaccines, which are intended to provide immunization to influenza A virus subtype H5N1. They are intended to discover pharmacological effects and identify any adverse reactions the vaccines may achieve in humans. Current status of H5N1 candidate vaccines Candidate vaccines were developed in the United States and the United Kingdom during 2003 for protection against the strain that was isolated from humans in Hong Kong in February 2003 but the 2003 strain died out in 2004 making the vaccine of little use. In April 2004, WHO made an H5N1 prototype seed strain available to manufacturers. In August 2006, WHO changed the prototype strains and now offers three new prototype strains which represent three of the six subclades of the clade 2 virus which have been responsible for many of the human cases that have occurred since 2005. The National Institute of Allergy and Infectious Diseases (NIAID) awarded H5N1 vaccine contracts t ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Anifrolumab
Anifrolumab, sold under the brand name Saphnelo, is a monoclonal antibody used for the treatment of systemic lupus erythematosus. It binds to the type I interferon receptor, blocking the activity of type I interferons such as interferon-α and interferon-β. Anifrolumab was approved for medical use in the United States in July 2021, and in the European Union in February 2022. The U.S. Food and Drug Administration considers it to be a first-in-class medication. Mechanism of Action In systemic lupus erythematosus, the body can produce a great amount of type 1 interferon, which activates the immune system excessively and creates problems for lupus patients. Anifrolumab acts to block IFN-1 from sending signals to other immune cells, which prevents the body from being attacked by itself. Adverse effects The most common adverse effect was shingles, which occurred in 5% of patients in the low-dose group, to 10% in the high-dose group, and to 2% in the placebo group. Overall adver ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Benralizumab
Benralizumab, sold under the brand name Fasenra, is a monoclonal antibody directed against the alpha chain of the interleukin-5 receptor ( CD125). It was developed by MedImmune for the treatment of asthma. It is currently marketed by Astrazeneca. Two phase III clinical trials of benralizumab reported meeting their primary endpoints in 2016. It was approved by the US Food and Drug Administration in November 2017 for the treatment of severe eosinophilic asthma. It was granted designation as an orphan drug by the Food and Drug Administration for treatment of eosinophilic oesophagitis in August 2019. Common adverse effects include injection site reactions, which were reported in 2.2% of patients (vs. 1.9% for placebo) in clinical trials. Clinical Trials In November 2024, the ABRA study found that a single dose of benralizumab could be more effective when injected at the point of exacerbation compared to currently used steroid tablets in patients at high risk of an asthma ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Tremelimumab
Tremelimumab, sold under the brand name Imjudo, is a fully human monoclonal antibody used for the treatment of hepatocellular carcinoma (a type of liver cancer). Tremelimumab is designed to attach to and block CTLA-4, a protein that controls the activity of T cells, which are part of the immune system (the body’s natural defenses). The most common side effects when used in combination with durvalumab include rash, pruritus (itching), diarrhea, abdominal (belly) pain, increased levels of liver enzymes, fever, hypothyroidism (an underactive thyroid gland), cough, peripheral edema (swelling especially of the ankles and feet) and increased level of lipase (an enzyme that helps digest fat, mainly made in the pancreas). Tremelimumab was approved for medical use in the United States in October 2022, and in the European Union in February 2023. Medical uses Tremelimumab is indicated, in combination with durvalumab, for the treatment of adults with unresectable hepatocellular carci ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Durvalumab
Durvalumab, sold under the brand name Imfinzi, is an anti-cancer medication used for treatment of various types of cancer. It was Drug development, developed by MedImmune, Medimmune/AstraZeneca. It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (PD-L1). Durvalumab is an Immune checkpoint#Immune checkpoint inhibitors, immune checkpoint inhibitor drug. It was approved in for medical use in the United States in May 2017, and in the European Union in September 2018. Medical uses The US Food and Drug Administration (FDA) approved durvalumab for certain types of bladder, lung, and biliary tract cancer: * Adults with locally advanced or metastatic urothelial carcinoma who either have disease progression during or following platinum-containing chemotherapy or have disease progression within twelve months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. * Adults with unresectable ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Gaithersburg, MD
Gaithersburg ( ) is a city in Montgomery County, Maryland, United States. At the time of the 2020 United States census, Gaithersburg had a population of 69,657, making it the third-largest incorporated city and the ninth-most populous community in the state. Gaithersburg is located to the northwest of Washington, D.C., and is considered a suburb and a primary city within the Washington metropolitan area. Gaithersburg was incorporated as a town in 1878 and as a city in 1968. The National Institute of Standards and Technology (NIST) is headquartered in Gaithersburg directly west of I-270. Other major employers in the city include IBM, Lockheed Martin Information Systems and Global Services business area headquarters, AstraZeneca. Gaithersburg is also the location of the garrison of the United States Army Reserve Legal Command. History Gaithersburg was settled in 1765 as a small agricultural settlement known as Log Town near the present day Summit Hall on Ralph Crabb's 1725 l ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Palivizumab
Palivizumab, sold under the brand name Synagis, is a monoclonal antibody produced by recombinant DNA technology used to prevent severe disease caused by respiratory syncytial virus (RSV) infections. It is recommended for infants at high-risk for RSV due to conditions such as prematurity or other medical problems including heart or lung diseases. The most common side effects include fever and rash. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged. Palivizumab is a humanized monoclonal antibody (IgG) directed against an epitope in the A antigenic site of the F protein of RSV. In two phase III clinical trials in the pediatric population, palivizumab reduced the risk of hospitalization due to RSV infection by 55% and 45%. Palivizumab is dosed once a month via intramuscular (IM) injection to be administered throughout the RSV season, which tends to start in late autumn or early winter i ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
